The aroA gene of Pasteurella haemolytica serotype Al was cloned by complementation of the aroA mutation in Escherichia coli K-12 strain AB2829. The nucleotide sequence of a 2.2-kb fragment encoding aroA predicted an open reading frame product 434 amino acids long that shows homology to other bacterial AroA proteins. Several strategies to inactivate aroA were unsuccessful. Gene replacement was finally achieved by constructing a replacement plasmid with aroA inactivated by insertion of a P. haemolytica ampicillin resistance fragment into a unique NdeI site in aroA. A hybrid plasmid was constructed by joining the aroA replacement plasmid with a 4.2-kb P. haemolytica plasmid which encodes streptomycin resistance. Following PhaI methylation, the replacement plasmid was introduced by electroporation into P. haemolytica NADC-D60, a plasmidless strain of serotype IA. Allelic exchange between the replacement plasmid and the chromosome of P. haemolytica gave rise to an ampicillin-resistant mutant which grew on chemically defined P. haemolytica medium supplemented with aromatic amino acids but failed to grow on the same medium lacking tryptophan. Southern blot analysis confirmed that aroA of the mutant was inactivated and that the mutant was without a plasmid.
The microorganism Pasteurella haemolytica biotype A, serotype 1, is the principal causative agent of pneumonic pasteurellosis in cattle. With the development of techniques for introducing exogenous DNA into P. haemolytica (5) , it now may be possible to produce site-specific mutations in this bacterium. Such mutants would prove extremely useful in investigating the molecular mechanisms of pathogenesis of P. haemolytica. Also, genetic manipulation of P. haemolytica may permit construction of rationally attenuated strains to test as live vaccine candidates.
Attenuated auxotrophic mutants were first described by Bacon et al. in 1950 (3) . In that study, it was reported that attenuated auxotrophs of Salmonella typhi defective in the aromatic amino acid biosynthetic pathway were avirulent in mice. Subsequently, it has been demonstrated in widely diverse bacteria that disrupting the aromatic amino acid biosynthetic pathway produces attenuated organisms. For example, attenuated strains of the invasive bacteria S. typhi (3), Salmonella typhimurium (11) , Shigella flexneri (22) , and Yersinia enterocolitica (4) were generated by introducing mutations in their respective aroA genes. Also, attenuation was produced in the noninvasive bacteria Bordetella pertussis (19) and Pastelurella mlultocida (13) through aroA inactivation. These aroA mutant strains are unable to synthesize chorismic acid from which p-aminobenzoic acid, dihydrobenzoate, and aromatic amino acids are produced. It is likely that the absence of one or more of these compounds in vivo is responsible for the poor growth of aroA mutants in the hosts.
The interest in constructing attenuated bacterial strains as vaccine candidates can be attributed to the superior protection afforded by live vaccines. In general, live vaccines elicit a stronger cell-mediated response in the host than do bacterins (7) . Also, the superior immunity provided by attenuated organisms compared with that provided by killed bacteria may be explained by induced expression of stress proteins and, Corresponding author. Phone: (515) 2739-820)0. Fax: (515) 239-8458. possibly, of certain toxins within the host. The immune response generated by live organisms would be directed against these abundant proteins and thereby provide better protection.
Because most vaccines to prevent pneumonic pasteurellosis are killed formulations, we decided to construct an aroA mutant of P. haenmolytica to test for efficacy as a live vaccine. To accomplish this goal, we cloned and determined the nucleotide sequence of P. haemolytica aroA. A number of replacement plasmids and hybrid plasmids consisting of a replacement plasmid joined to plasmids of P. haemolytica were constructed. Following methylation by PhaI methyltransferase, the plasmids were introduced into P. haemolytica. One of these constructs, a hybrid plasmid which joined the replacement plasmid harboring insertionally inactivated aroA to the P. haemolytica plasmid encoding streptomycin resistance, was used to produce an aroA mutant by gene replacement.
MATERIALS AND METHODS
Molecular cloning and Southern blot analysis of P. haemolytica aroA. Genomic DNA was prepared from P. haemolytica NADC-D60 by previously described methods (5) . Southern blotting of P. haemolytica restriction fragments fractionated by electrophoresis on 0.75% agarose was performed as described previously (5) . Blots (18) . A recombinant plasmid, pPharoAl, complemented AB2829 growth on M9 minimal medium containing phosphate buffer, 1 mM MgSO4, 0.1 mM CaCl2, 0.2% glucose, thiamine (10 ,ug/ml), 1.5% Noble agar (Difco), and 50 ,ug of ampicillin per ml (1) . ClaI-HindIII double digestion of pPHaroA1 produced a 2.2-kb fragment which when cloned into the AccI and Hindlll sites of pBluescript SK-gave rise to pPharoA2. The recombinant plasmid, pPharoA2, which also complemented growth of AB2829 on minimal plates, was used to sequence P. haemolytica aroA. Plasmid pPharoA3 was generated by subcloning the 2.2-kb fragment of pPharoA2 into pBC SK+ (Stratagene Inc. Construction of replacement plasmids and the production and characterization of a P. haemolytica aroA mutant. Construction of the replacement plasmid pPhAaroACmr (Table 1) and the hybrid plasmid pPhAaroACmrpD80 is described in the preceding study (5) . The steps involved in the construction of the other plasmids used in this study (Table 1) Plasmid pD80, a 4.2-kb ampicillin resistance (Ampr) encoding plasmid of P. haemolytica (2, 14) , was partially digested with Sau3A and ligated into the BamHI site of pBC SK+ (Stratagene Inc.). The ligation mix was diluted 1:10 in distilled water and electroporated into E. coli DH-1OB (BRL). After recovery in 1 ml of SOC medium containing 2% Bacto Tryptone, 0.5% Bacto Yeast Extract, 8 mM NaCl, 2.5 mM KCI, 10 mM MgCl2, and 20 mM glucose (15) , at 37°C the cells were spread onto B-broth plates, containing 1% Bacto Tryptone, 0.8% NaCl, 2% Difco agar, thiamine (10 ,Ig/ml), 0.002% 5-chloro-4-bromo-3-indolyl-,3-D-galactopyranoside (X-Gal), 100 ,uM isopropyl-,3-D-thiogalactopyranoside (IPTG), and 50 ,ug of ampicillin per ml. Plasmid pPhAmpr contained a 2.2-kb P. haemolytica fragment which imparted ampicillin resistance to E. coli to up to 100 ,ug/ml. Plasmid pPhAmpr was digested with HindlIl and XbaI, and the fragment ends were made blunt by incubation with deoxynucleoside triphosphates and the large Klenow fragment of E. coli polymerase I. The fragment encoding ampicillin resistance was electroeluted and used to inactivate aroA of pPharoA3. To do so, pPharoA3 was digested 2012 TATUM ET AL.
CONSTRUCTION OF AN aroA MUTANT OF P. HAEMOLYTICA at a unique NdeI site contained in aroA (see Fig. 2 ) and the fragment ends were made blunt as described above. The ampicillin resistance fragment was blunt end ligated with pPharoA3 to generate pPharoA -Ampr. To produce a hybrid plasmid, pPharoA-Ampr was digested with Hindlll and dephosphorylated with calf alkaline phosphatase. A 4.2-kb plasmid, designated pD70, which encodes streptomycin resistance (Smr) (6) , was isolated from P. haemolytica NADC-D70 by previously described methods. Plasmid pD70 was digested at a unique HindlIl recognition site and ligated with Hindllldigested pPharoA --Ampr to generate the hybrid plasmid pPharoA AmprpD70. Plasmid pPharoA -AmprpD70 was electroporated into E. coli PhaIMtase (Table 1 ). Strain PhaIMtase is E. coli DH-1OB (BRL) which contains the PhaI methyltransferase gene on cosmid vector pLAFRX, which was derived from pLAFR2 (9) . Then the PhaI methyl-modified hybrid plasmid was isolated by the alkaline lysis method (15) and CsCl purified. One microgram of plasmid and 100 ,ul of P. haemolytica NADC-D60 (a plasmidless isolate of serotype Al) were transferred to a 0.1-cm cuvette and electroporated at 15,000
V/cm with 800 Q. The resultant time constant was approximately 9 mc. Cells were transferred to I ml of Bacto Columbia broth (Difco Labs, Detroit, Mich.) and incubated at 37°C for 1 h. One milliliter of Columbia broth containing 20 jig of ampicillin was added, and the cells were incubated for an additional hour and then spread on Difco Columbia blood agar plates containing 5% bovine blood and 10 jig of ampicillin per ml. Eight ampicillin-resistant P. haemolytica colonies were isolated after incubation at 37°C for 18 h. The colonies were then transferred to Bacto Columbia broth containing 1 ,ug of ampicillin per ml and incubated at 37°C. Daily passage into fresh medium containing I jLg of ampicillin per ml was carried out for 3 days, at which time the cultures were transferred onto Columbia broth blood agar plates containing 10 ,ug of ampicillin per ml and incubated at 37°C overnight. The next day the colonies were replica plated onto Columbia broth blood agar plates containing 10 jLg of chloramphenicol per ml or 50 jLg of streptomycin per ml. The colonies were also replica plated onto a chemically defined medium for P. haenolytica cultivation (23) . The defined medium contained 15 amino acids and included the aromatic amino acids phenylalanine and tyrosine but not tryptophan. Clones unable to grow on the chemically defined medium for P. haemolytica cultivation were presumed to be aroA mutants. Genomic DNAs isolated from clones with Ampr Cm' Sms AroA -phenotypes were analyzed by Southern blotting. Southern blotting was performed as described previously with the exception that after hybridization the membranes were washed twice for 10 min each in Ix SSC-0.1% SDS at 42°C and twice more for 15 min each in 0.1X SSC-0.1% SDS at 65°C. Nucleotide sequence accession number. The P. haemolytica aroA sequence data reported here have been deposited in GenBank under accession number U03068.
RESULTS AND DISCUSSION Cloning of P. haemolytica aroA. Restriction fragments of P. haemolytica genomic DNA were fractionated by agarose gel electrophoresis. The fragments were probed for homology to E. coli aroA by Southern analysis. Under conditions of low stringency, a 3.2-kb HindIll fragment of P. haemolytica genomic DNA hybridized with radiolabeled E. coli aroA (Fig.   1 
Nucleotide sequence of and deduced amino acid sequence encoded by P. haemolytica aroA.
Since we have shown that the Phal-methylated hybrid plasmid consisting of plasmid pPhAaroACmr joined with pD80 (Ampr) from P. haemolytica could be used to transform P. haemolytica NADC-D60 (5), we investigated whether aroA mutants might arise after transformation with the hybrid plasmid. The hybrid plasmid was found, however, to be stable after multiple passages without selection, so no recombinant P. haemolytica could be detected. Since previous investigation demonstrated that the hybrid plasmid more efficiently transforms P. haemolytica when isolated from the homologous bacterium than when isolated from E. coli (5) , an attempt was made to generate a suicide plasmid from the hybrid plasmid isolated from P. haemolytica. Linear and T4 ligase-treated relaxed circular pPhAaroACmr plasmids were generated from the hybrid plasmid after restriction enzyme digestion. Neither version resulted in Cmr colonies upon reintroduction into P.
haemolytica. Although pPhAaroACmr was treated with the Klenow fragment and deoxynucleoside triphosphates prior to treatment with T4 ligase, examination showed that most of the sample remained linear rather than circular. The results, then, are not totally unexpected, since there have been few reports of the successful establishment of linear DNA into bacteria (10, 16, 24) .
Because initial selection on chloramphenicol has been inferior to selection on ampicillin in our laboratory (5), we decided to change the antibiotic resistance cassette in our replacement plasmid from Cmr to Ampr (5) . A Sau3A-generated 2.2-kb fragment from pD80 from P. haemolytica which conferred ampicillin resistance was cloned into the BamHI site of pBC SK, resulting in pPhAmpr. To demonstrate that pPhAmpr did not possess the pD80 origin of replication, pPhAmpr was isolated from E. coli containing PhaI methyltransferase by methods described previously, CsCl purified, and introduced into P. haemolytica by electroporation. Since the PhaI-methylated plasmid did not confer ampicillin resistance to P. haemolytica NADC-D60, we concluded that the fragment encoding (Fig. 3) , streptomycin confirmed that the two clones were Ampr, Cms ed to generate Sms. Also, the two Ampr clones were spread onto plates of chemically defined medium for P. haemolytica cultivation (23 60, 1994 the parent strain. The E. coli aroA mutant AB2829 also required tryptophan to grow on the chemically defined medium for P. haemolytica cultivation. DNAs from the two colonies with Ampr Cms Sms aroA mutant phenotypes were analyzed by Southern blotting. The results indicated that both had insertionally inactivated aroA genes. Moreover, Southern blotting also confirmed that both pD70 and pBC SK sequences were no longer present in the aroA mutants (Fig. 4) .
The experimental approach that successfully produced an aroA mutant required repeated passage of P. haemolytica transformed with the hybrid plasmid pPharoA -AmprpD70. Although this hybrid plasmid was able to replicate in P. haemolytica, improving the chance for recombination, its instability allowed recovery of plasmidless aroA mutants. The failure of the replacement plasmid alone to generate antibiotic-resistant colonies of P. haemolytica may be explained by the low transformation frequencies of Phal-methylated plasmids which were insufficient to routinely produce mutants by the rare event of homologous recombination. In other bacteria, conjugative suicide vectors have been shown to be highly efficient for gene replacement constructions. For this reason, we constructed a derivative of pPharoA -AmprpD70 which contained mob (20) , the P-type-specific recognition site for mobilization, inserted in the unique BamHI site of the polylinker. The hybrid plasmid was mobilized from E. coli S17-1 (20) with and without PhaI methyltransferase on a compatible vector. No P. haemolytica transconjugates were detected from donors lacking PhaI methyltransferase; approximately 10-9 arose following matings with donors which contained PhaI methyltransferase. Plasmid recovered from the transconjugates apparently had undergone rearrangement, because their apparent molecular weights differed from that of the donor plasmid (data not shown).
To our knowledge, the work described here is the first report of site-directed gene replacement in P. haemolytica. Whether the P. haemolytica aroA mutant is attenuated is yet to be determined. Future work aimed at assessing the suitability of the aroA mutant as a live vaccine against pneumonic pasteurellosis in cattle and sheep is planned.
